Cowen & Co. Believes Voyager Therapeutics Inc (VYGR) Still Has Room to Grow


Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Voyager Therapeutics Inc (VYGR) today. The company’s shares opened today at $23.92, close to its 52-week high of $24.60.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 9.7% and a 51.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.

Currently, the analyst consensus on Voyager Therapeutics Inc is a Strong Buy with an average price target of $24.67, implying a 3.1% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $22 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.60 and a one-year low of $7.76. Currently, Voyager Therapeutics Inc has an average volume of 492K.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VYGR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts